Israeli device freezes malignant liver and kidney tumors
US doctors already use IceCure’s ProSense to destroy benign breast lumps. Soon they’ll be using it for malignant liver and kidney tumors
ISRAEL21c , Bio and Archives--January 22, 2020
Health and Medicine | Comments | Reader Friendly | Subscribe | Email Us
In July 2012, ISRAEL21c wrote about a novel device from Caesarea-based IceCure Medical that was revolutionizing how American doctors remove benign breast lumps.
The device uses minimally invasive cryoablation to destroy the tumor by freezing it rather than surgically removing it.
Since then, IceCure’s ProSense system has expanded its applications dramatically.ProSense uses cryoablation to freeze out small tumors
The device currently is used in Asia, Israel and Europe to zap early-stage cancerous liver and kidney tumors. IceCure recently received US Food and Drug Administration (FDA) approval to do the same in the United States. Just how soon ProSense will be available in US treatment centers for the two new applications is hard to say. IceCure Medical VP of Business Development and Global Marketing Tlalit Bussi Tel Tzure tells ISRAEL21c that the insurance reimbursement codes are in place for both indications. Now the public company is beginning to “build the right infrastructure to start our commercial phase for these indications” in America from its New Jersey branch office. Mission: treating more patients Meantime, IceCure’s ProSense device is being used in Europe for breast, kidney, lung and bone cancer. And more than 300 lung cancer patients and 300 breast cancer patients have been treated with ProSense in Japan.-- More...View Comments
ISRAEL21c——Bio and Archives
ISRAEL21c was founded in 2001, in the wake of the Second Intifada, to broaden public understanding of Israel beyond typical portrayals in the mainstream media.
The organization’s founders – Israeli-American technology executives – understood the great power of the Internet and developed a first-of-its kind online product with global appeal and reach.